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Background: The possible association between pulmonary tuber-
culosis (TB) and lung cancer development has been studied for
several decades. However, the association between epidermal
growth factor receptor (EGFR) mutation status and pulmonary TB in
patients with adenocarcinoma of the lungs is unknown.
Methods: We reviewed the data of our patients with adenocarci-
noma of the lungs who had a clinical history of pulmonary TB or old
TB lesions shown on chest computed tomography scan and evalu-
ated the association between tumor EGFR mutation status and
pulmonary TB.
Results: From June 1999 to January 2011, there were 275 patients
with pulmonary adenocarcinoma with tumor EGFR mutation data
available for analysis. Of them, 191 patients had EGFR mutations,
17 had a clinical history of pulmonary TB infection, 72 had old TB
lesions on chest computed tomography scans, and 14 had scar
cancer. Patients with old TB lesions had a higher incidence of EGFR
mutation than those without (p  0.018). Exon 19 deletions oc-
curred more frequently in patients with old TB lesions than in
patients without (p  0.001). Those patients with old TB lesions
who had EGFR mutations or exon 19 mutations survived longer than
those who did not (p 0.014 and 0.001, respectively). Patients with
exon 19 deletions and old TB lesions showed no survival difference
compared with those with exon 19 deletions and without old TB
lesions (p  0.271).
Conclusions: Patients with pulmonary adenocarcinoma who had
scar cancer or had old TB lesions had a higher probability of having
EGFR mutations, especially exon 19 deletions.
Key Words: Epidermal growth factor receptor, Non-small cell lung
cancer, Tuberculosis.
(J Thorac Oncol. 2012;7: 299–305)
Lung cancer is the leading cause of cancer death throughoutthe world. Approximately 12.4% of all newly diagnosed
cancer cases are lung cancers, and lung cancer accounts for
29% of all cancer deaths.1 Tuberculosis (TB) is one of the
major causes of death among infectious diseases and remains
a global public health threat. The majority of TB infections
are pulmonary TB. It has been proposed that pulmonary TB
infection may exist as a chronic inflammatory process that is
associated with an increased risk of lung cancer. This is
because the pulmonary inflammation and fibrosis may induce
genetic damage, which leads to carcinogenesis of the pulmo-
nary parenchymal tissue.2–5 It has been reported that some
cases of lung cancer, usually adenocarcinoma in type, that
arise from pulmonary scars were the result of healed pulmo-
nary TB infection.6–8
The frequency of epidermal growth factor receptor
(EGFR) mutations in non-small cell lung cancer ranges from
5 to 30% and depends on the population studied.9–12 Patients
with lung cancer whose tumors exhibited EGFR-activating
mutations had approximately 75% response rate when treated
with EGFR-tyrosine kinase inhibitors (TKIs), whereas those
patients without EGFR-activating mutations responded to
EGFR-TKI poorly.9,13,14 In addition, patients with lung can-
cer with tumor EGFR-activating mutations survived longer
than those without.15,16
The incidence of tumor EGFR mutations was found to
be higher in East Asian countries, such as Taiwan, as was the
prevalence of pulmonary TB infection.17–19 However, there
was no report on tumor EGFR mutation status in patients with
lung cancer with or without pulmonary TB, nor was EGFR
mutation status correlated with pulmonary TB. The clinical
characteristics of patients with lung cancer who have pulmo-
nary TB and an EGFR mutation have also not been discussed.
We therefore conducted this retrospective study to determine
whether there is a difference in the clinical manifestations and
patient survival between tumor EGFR mutation status and
pulmonary TB.
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PATIENTS AND METHODS
We retrospectively reviewed the chart records of our
patients with pulmonary adenocarcinoma who had received
diagnosis, staging, and treatment in our hospital from 1999 to
2011. Histories of having been diagnosed with pulmonary TB
and chest computed tomography (CT) images compatible
with previous tuberculous infection were also recorded. A
clinical history of pulmonary TB is defined as a consistent
chest image pattern and having received anti-TB treatment
previously. This review was approved by the institutional
review board of our hospital (VGHIRB 2011-04-0151A).
Lung cancer staging was evaluated according to the sixth
edition of the tumor node metastasis staging system for
non-small cell lung cancer. Patients with a histological diag-
nosis of adenocarcinoma of the lungs were classified as
patients with a history of pulmonary TB disease or not,
patients with chest CT images revealing old pulmonary TB
lesion(s) or not, and patients with chest CT images suggestive
of scar cancer or not.
The existence and location of pulmonary TB lesions
were determined on the basis of chest CT scan findings. All
images were analyzed by three independent reviewers. Chest
CT scans were evaluated for fibrotic change, fibronodular
lesions, pleural thickening, calcified nodules, scars, the loca-
tion of the primary tumor, and TB lesions in the same or
TABLE 1. Characteristics of All Cases
Group A Group B Group C Total
Patient no. (%) 17 (6.2) 72 (26.2) 199 (72.4) 275
Gender (%)
Male 13 42 87 131 (47.6)
Female 4 30 112 144 (52.4)
Age, mean
(range), yr
73.05 (50–94) 68.43 (46–94) 61.6 (30–91) 63.5 (30–94)
With smoking
history
5 25 48 74
Performance status
(ECOG)
0 3 11 56 68
1 9 47 126 176
2 5 14 17 31
Lung cancer
staging
I 0 3 20 23
II 0 1 4 5
IIIa 2 6 12 19
IIIb 0 4 20 24
IV 15 58 143 204
Scar cancer 4 14 0 14
Location of lung
cancer and
TBa
Ipsilateral 11 55 47 59
Same lobe 8 40 32 40
Contralateral 0 13 13 13
Location of lung
cancer
Central 6 28 80 109
Peripheral 11 44 119 166
EGFR mutation (%)
With any
mutation
15 58 129 191 (69.5)
With exon 19
mutation
10 49 66 118 (42.9)
With L858R point
mutation
4 6 51 59 (21.5)
Other mutationb 3 6 12 18 (6.5)
Wild type 2 14 70 84 (30.5)
Received
EGFR-TKI
15 62 152 218
a Ipsilateral, the main lesion of PTB was located in the same hemithorax as that of
lung cancer; contralateral, the main lesion of PTB lay in the hemithorax contralateral to
that of cancer; and same lobe, PTB affected the same lobe as that of lung cancer.
b With tumor EGFR mutation other than an exon 19 mutation and L858R point
mutation.
Group A, patients with a history of pulmonary TB disease; group B, patients with
old pulmonary TB lesions on chest CT scan; group C, patients without history of
pulmonary TB disease and old pulmonary TB lesions on chest CT scan; ECOG, Eastern
Cooperative Oncology Group; TB, tuberculosis; EGFR, epidermal growth factor recep-
tor; CT, computed tomography; PTB, pulmonary tuberculosis.
TABLE 2. Types of EGFR Mutations Detected
Exon
No.
Detected
No. of
Each Exon
Total
No.
Exon 18 mutation 8 191a
A702V 1
G719A 2
G719C 1
G719D 1
G719S 2
E709A; G719S 1
Exon 19 deletionb 118 118
Exon 20 mutation 10
A763T 1
D761Q 2
D761Q; L782F; E804K 1
Insertion 6 bases (ggcaca) between
2310 and 2311
1
Insertion 6 bases (cacgtg) between
2322 and 2323
1
Insertion 9 bases (tgtggacag) between
2303 to 2304
1
Insertion 9 bases (ccagcgtgg) between
2308 and 2309
1
Mutation at base 2453(gc); C818S 1
T790M 1
Exon 21 mutation 77
L858R mutationb,c 59
A839F; Q849H 1
Deletion of one base(g) at 2507 1
L861Q 3
Polymorphism at base 2449(tc);
2581(ct), H850H; L861L
1
R836Pc 13
S768I 1
a Many patients have several different types of mutation at the same time.
b Eleven patients with both exon 19 deletions and exon 21 L858R.
c Two patients with R836P also have L858R mutation, and they were not included
in 18 patients with exon 21 mutation other than L858R point mutation.
EGFR, epidermal growth factor receptor.
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different lobe of the primary lesion of lung cancer. Lesions
with calcified granulomas, fibronodular lesions, or pleural
thickening in favor of previous granulomatous inflammation
were regarded as old TB lesions.20 Scar cancer included lung
cancer arising from old pulmonary TB lesions that had thus
merged with fibrotic scars or granuloma lesions.21 After
reviewing the chest CT scans, the three reviewers reached a
final diagnosis by consensus.
EGFR mutation analysis was performed with nucleo-
tide sequence analysis.22 The VarientSEQr Resequencing
Primer Set was selected for mutational analysis of the ty-
rosine kinase domain and exons 18 to 21 of the EGFR gene.
Genomic DNA was extracted from paraffin blocks, exons 18
to 21 were amplified, and uncloned polymerase chain reac-
tion fragments were sequenced and analyzed in both sense
and antisense directions for the presence of heterozygous
mutations. Normal control DNA provided by the ABI Com-
pany was used for wild-type control. All the sequence vari-
ations were confirmed by multiple, independent polymerase
chain reaction amplifications and repeated sequencing reac-
tions. Tumor EGFR mutations were defined as those with
exons 18 to 21 mutations. The associations between EGFR
mutation and past pulmonary TB and old TB lesions were
evaluated using Pearson’s 2 test and multivariate logistic
regression analysis.
Survival was measured from the date of initiation of
treatment to the date of death or last follow-up. For statistical
analysis, the Kaplan-Meier method with a log-rank test and
Cox proportional hazard model were used for survival anal-
ysis.
RESULTS
From June 1999 to January 2011, 275 patients with
adenocarcinoma of the lung had tumor EGFR mutation status
data available for analysis. Of these patients, 131 (47.6%)
were men and 144 (52.4%) were women (Table 1). Among
all patients, 17 (6.2%) had a history of pulmonary TB, 72
(26.2%) had old TB lesions on the chest CT scan, and 14
(5.1%) had scar cancer. Of all patients, 191 (69.5%) had an
EGFR mutation (118 exon 19 deletions, 59 exon 21 L858R
point mutation, including 11 patients with both exon 19
deletions and exon 21 L858R, 8 exon 18 mutations, and 10
exon 20 mutations; Tables 1 and 2), and 84 patients (30.5%)
were EGFR wild type.
Patients with old TB lesions found on chest CT scans
had a higher incidence of EGFR mutations (58 patients,
80.6%) than those without (133 patients, 65.5%; p  0.018,
Table 3). All patients with scar cancer had an EGFR muta-
tion, but those with lung cancer other than scar cancer had a
lower proportion of EGFR mutations (100% versus 67.8%,
p  0.007). Exon 19 deletions occurred more frequently in
patients with old TB lesions found on chest CT scans than in
patients without (68.1% versus 34%; p  0.001). Patients
with scar cancer had a higher incidence of exon 19 deletions
(13 of 14) than the remaining patients without scar cancer
(92.9% versus 40.2%; p  0.001). A lower proportion of
patients with old TB lesions found on chest CT scans had
L858R mutations than patients without (8.3% versus 26.1%,
p  0.007). Thus, old TB lesions and scar cancer had a
statistically significant association with EGFR mutation, es-
pecially exon 19 deletions. The odds ratios for exon 19
deletions were 19.31 (95% CI: 2.49–149.87) among patients
with scar cancer, 4.14 (95% CI: 2.33–7.35) among patients
with old TB lesions on chest CT scans, and 1.99 (95% CI:
0.73–5.38) among patients with a history of pulmonary TB.
TABLE 3. Association between EGFR Mutation and Pulmonary Tuberculosis
EGFR Mutation Exon 19 Mutation Exon 21 Mutation
Yes Noa p Yes No p L858R () Others ()b No p
History of PTB, n (%)
Yes 15 (88.2) 2 (11.8) 0.105 10 (58.8) 7 (41.2) 0.209 4 (23.5) 3 (17.6) 10 (58.8) 0.143
No 176 (68.2) 82 (31.8) 108 (41.9) 150 (58.1) 55 (21.3) 15 (5.8) 188 (72.9)
Old TB lesions on chest CT scan, n (%)
Yes 58 (80.6) 14 (19.4) 0.018 49 (68.1) 23 (31.9) 0.001 6 (8.3) 5 (6.9) 61 (84.7) 0.007
No 133 (65.5) 70 (34.5) 69 (34) 134 (66) 53 (26.1) 13 (6.4) 137 (67.5)
Scar cancer, n (%)
Yes 14 (100) 0 (0) 0.007 13 (92.9) 1 (7.1) 0.001 0 (0) 2 (14.3) 12 (85.7) 0.086
No 177 (67.8) 84 (32.2) 105 (40.2) 156 (59.8) 59 (22.6) 16 (6.1) 186 (71.3)
a EGFR wild-type.
b With exon 21 mutation other than L858R point mutation.
PTB, pulmonary tuberculosis; EGFR, epidermal growth factor receptor; TB, tuberculosis; CT, computed tomography.
TABLE 4. Multivariate Analysis for Prediction of Tumor
EGFR Mutation
Variables (No. of Patients)
Multivariate
Logistic Regression
pOdds Ratio 95% CI
Age (70/70) (99/176), yr 1.13 0.64–1.998 0.684
Sex (male/female) (131/144) 1.15 0.62–2.1 0.665
Smoking (yes/no) (74/201) 1.06 0.53–2.13 0.876
PTB history (yes/no) (17/258) 2.33 0.49–11.05 0.286
Old TB lesions (yes/no) (72/203) 1.83 0.92–3.62 0.038
PTB, pulmonary tuberculosis; EGFR, epidermal growth factor receptor; TB, tuber-
culosis; CI, confidence interval.
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Multivariate analysis for prediction of tumor EGFR mutation
was performed. After adjusting for possible confounders, the
multivariate analysis revealed that the odds ratio for tumor
EGFR mutation among patients with old TB lesions was 1.83
(95% CI: 0.92–3.62; p  0.038; Table 4).
Among patients with old TB lesions found on chest CT
scans, there was a higher proportion of patients with an
EGFR mutation (p  0.039), especially exon 19 deletions
(p  0.001; Table 5), and especially in patients who had lung
cancer and old TB lesions in the same lobe or same side of the
lung, than those who had lung cancer and old TB lesions in
the opposite side of the lung. Most of the patients with lung
cancer and old TB lesions in the same lobe of the lung did not
have L858R mutations (p  0.022): only 4 of 40 patients
(10%) who had lung cancer and old TB lesions in the same
lobe had L858R mutations.
Survival analysis showed that patients with adenocar-
cinoma who had old TB lesions (n  72) survived for a
FIGURE 1. Survival curve of all 274 patients with adenocar-
cinoma. Patients who had old TB lesions (n  72) survived
for a shorter period than those who did not (n  202;
1-year survival rate 77% versus 85.8%, p  0.015. TB, tu-
berculosis.
TABLE 5. The Association between EGFR Mutation and the Location of Pulmonary Tuberculosis
EGFR Mutation Exon 19 Mutation Exon 21 Mutation
Yes Noa p Yes No p L858R () Other ()b No p
Location of lung cancer and PTB, n (%)c
Same lobe 34 (85) 6 (15) 0.039 29 (72.5) 11 (27.5) 0.001 4 (10) 2 (5) 34 (85) 0.022
Ipsilateral 16 (84.2) 3 (15.8) 12 (63.2) 7 (36.8) 2 (10.5) 3 (15.8) 14 (73.7)
Contralateral 8 (61.5) 5 (38.5) 8 (61.5) 5 (38.5) 0 (0) 0 (0) 13 (100)
No TB lesions 133 (65.5) 70 (34.5) 69 (34) 134 (66) 53 (26.1) 13 (6.4) 137 (67.5)
a EGFR wild type.
b With exon 21 mutation other than L858R point mutation.
c Ipsilateral, the main lesion of PTB was located in the same hemithorax as that of lung cancer; contralateral, the main lesion of PTB lay in the hemithorax contralateral to that
of cancer; and same lobe, PTB affected the same lobe as that of lung cancer.
PTB, pulmonary tuberculosis; EGFR, epidermal growth factor receptor; TB, tuberculosis.
TABLE 6. Survival Analysis in All Cases and Subgroups
Patient
No.
1-Yr
Survival
Rate
(%)
Median
Survival, mo
(95% CI) p
All cases
With old PTB lesions 72 77 44.4 (22.5–66.2) 0.015
Without old PTB lesions 202 85.8 NR
With exon 19 deletion 117 88.6 68.8 (34.3–103.4) 0.015
With EGFR wild type 84 76.3 NR
With exon 19 deletion or
L858Ra
121 87 NR 0.025
With EGFR wild type 84 76.3 NR
Patients with EGFR wild type
With old PTB lesions 14 35.4 8.5 (7.3–9.7) 0.009
Without old PTB lesions 70 82.1 NR
Patients with EGFR mutation
With old PTB lesions 58 84.6 44.4 (31.6–57.1) 0.035
Without old PTB lesions 133 86.7 NR
Patients with exon 19 mutation 11
With old PTB lesions 49 90.4 44.4 (31.6–57.1) 0.271
Without old PTB lesions 67 83.3 NR
Patients with exon 19 deletion
or L858Ra
With old PTB lesions 34 78.8 44.4 (11.2–77.4) 0.052
Without old PTB lesions 87 88.1 NR
Patients with old PTB lesions
With EGFR mutation 58 84.6 44.4 (31.6–57.1) 0.014
Without EGFR mutation 14 35.4 8.5 (7.3–9.7)
With exon 19 mutation 49 90.4 44.4 (31.6–57.1) 0.001
Without exon 19 mutation 23 43.1 8.5 (6.9–10.2)
With L858R mutation 6 66.7 44.4 (22.3–66.4) 0.689
Without L858R mutation 66 78 NR
a Either exon 19 deletions or exon 21 L858R mutation.
PTB, pulmonary tuberculosis; CI, confidence interval; NR, not reached; EGFR,
epidermal growth factor receptor.
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shorter period than those who did not (n  202; 1-year
survival rate 77% versus 85.8%; p  0.015; Figure 1; Table
6) in the entire study population based on the unadjusted
analysis. Similar results were obtained from Cox regression
analysis adjusted for covariates, including EGFR mutations
and tumor stage (Table 7). Among all patients’ characteris-
tics, having old TB lesions coincide with shorter overall
survival than its contrary, independent of having EGFR
mutation or not. On the other hand, overall survival was not
influenced by the patient’s gender, age, smoking history,
tumor stage, performance status, and EGFR-TKIs treatment.
When the survival time of patients with exon 19 deletions
(n  117) was compared with that of EGFR wild-type
patients (n  84), the former had survived longer than the
latter (1-year survival rate 88.6% versus 76.3%; p  0.015;
Figure 2; Table 6).
When survival was compared between patients who
had EGFR mutations (either exon 19 deletions or L858R
mutation) and those who were EGFR wild type, those who
had EGFR mutations (n  121) had survived longer than
those who had EGFR wild type (n  84; 1-year survival rate
87% versus 76.3%; p  0.025, median survival had not been
reached; Table 6).
In patients with tumor EGFR wild type, those who had
old TB lesions (n  14) survived for a shorter period than
those did not (n  70; 1-year survival rate 35.4% versus
82.1%; p  0.009; Figure 3; Table 6). Among patients with
EGFR mutations, those who had old TB lesions (n  58)
survived for a shorter period than those who did not (n 133;
1-year survival rate 84.6% versus 86.7%; p  0.035; Figure
4; Table 6). However, with or without old TB lesions did not
affect overall survival among patients with exon 19 deletions
(p  0.271; Table 6). In patients with old TB lesions, those
who had EGFR mutations or exon 19 mutations survived
longer than those who did not have mutations. (p 0.014 and
0.001, respectively; Table 6).
DISCUSSION
This is the first study to investigate the association
between tumor EGFR mutations and pulmonary TB. The
coexistence of pulmonary TB and lung cancer has been noted
for many decades and poses considerable challenges for the
diagnosis and treatment. Many studies have suggested that
pulmonary TB plays an important role in the formation of
follow-on lung cancer and that pulmonary TB is associated
with an increased risk of lung cancer. The pathogenic linkage
between pulmonary TB and lung cancer is still unclear. A
chronic inflammatory process because of latent TB infection
may serve as a cause of lung carcinogenesis and results in
remodeling of lung tissue, activation of an atypical differen-
tiation pathway, and finally malignant transformation.23 Ar-
FIGURE 2. Survival curve of patients with EGFR exon 19
deletions or EGFR wild type. When the survival time of pa-
tients with exon 19 deletions (n  117) was compared with
that of EGFR wild-type patients (n  84), those who had
exon 19 deletions survived longer than those with EGFR wild
type (1-year survival rate 88.6% versus 76.3%, p  0.015).
EGFR, epidermal growth factor receptor.
TABLE 7. Overall Survival Based on Clinical Characteristics
Factor (No. of Patients)
1-Yr
Survival
Rate (%)
Univariate
Analysis
Multivariate
Analysis
HR pa HR pb
Old TB lesions 1.884 0.015 2.12 0.006
Yes (72) 77
No (202) 85.8
EGFR mutations 0.536 0.019 0.45 0.004
Yes (191) 86.8
No (83) 75.9
Gender 1.121 0.657
Male (130) 84
Female (144) 83.3
Age 1.061 0.826
70 (99) 78.9
70 (175) 86.2
Smoking 1.598 0.076
Yes (74) 76.1
No (200) 86.4
Tumor stage 0.412 0.05 0.43 0.072
IIIIa (46) 87.6
IIIbIV (228) 82.8
Performance status
(ECOG)
0.921 0.83
01 (243) 84.5
2 (31) 77.2
EGFR-TKI 0.845 0.617
Yes (218) 83.9
No (56) 82.7
a Kaplan-Meier analysis by log-rank test.
b Cox regression.
ECOG, Eastern Cooperative Oncology Group; OS, overall survival; HR, hazard
ratio; TKI, tyrosine kinase inhibitor; TB, tuberculosis; EGFR, epidermal growth factor
receptor.
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dies24 suggested that lung scarring occurred as a result of
spontaneous healing after repeated pulmonary TB infections
and produced a favorable environment for tumor growth.
Nalbandian et al.23 postulated that chronic TB infection may
lead to DNA-damaging reactive oxygen and nitrogen species
and that the MTB-infected macrophages produce a most
potent member of the epidermal growth factor family, epi-
regulin, which may play an important role as a paracrine
growth factor during the initial steps of carcinogenesis. Ed-
wards and Carlile25 suggested that a proportion of lung
cancers arise at the edge of preexisting pulmonary scars and
that the lung parenchymal scarring could promote atypical
epithelial cell proliferation and metaplasia in the terminal
airspace. Our findings of a significant association between
EGFR mutation and pulmonary TB further support these
hypotheses: patients with adenocarcinoma, who had scar
cancer and old TB lesions, had a higher probability of having
EGFR mutations, especially exon 19 deletions. Our data also
showed that patients with scar cancer had the highest odds
ratios (19.31) for exon 19 deletions, followed by those with
old TB lesions (odds ratio of 4.14) and a history of pulmonary
TB (odds ratio of 1.99). The scarring process of old TB
lesions may play an important role in the formation of lung
cancer. A previous study also showed that individuals with a
clinical history of TB had a fivefold higher risk of lung cancer
than a control group.26
Because patients with old TB lesions on chest CT scans
had a lower probability of having a L858R point mutation
(p 0.007) than those without TB lesions on chest CT scans,
pulmonary TB may be related to the formation of EGFR
mutations but not all types of EGFR mutations. On the basis
of our findings, the inflammatory process of pulmonary TB
may lead to cellular exon 19 deletions but not exon 21 L858R
mutations.
Previous studies have suggested that the development
of bronchogenic carcinoma tends to be localized in the lobe
of the lung that was involved in the pulmonary TB infec-
tion.27 Our study revealed a similar result, and we also found
that patients with old pulmonary TB lesions at the same lobe
or on the same side of the lung as the cancer had more tumor
EGFR mutations (p  0.039), and especially exon 19 dele-
tions (p  0.001), than on the opposite side of the lung.
According to our data, when the location of the lung cancer
was closer to the old TB lesions, the proportion of tumor
EGFR mutations, especially exon 19 deletions, was higher.
These results suggested that the more chronic the inflamma-
tory process the lung suffered from TB, the more EGFR
mutations, especially exon 19 deletions, these patients had.
A previous study reported that survival was worse in
patients with lung cancer with active pulmonary TB.6 This
study showed that patients with old TB lesions had shorter
overall survival than those without. Among patients with old
TB lesions, those who had tumor EGFR mutations or exon 19
deletions survived longer than those who did not (p  0.014
and 0.001, respectively), but the presence of an L858R
mutation did not have an effect on overall survival (p 
0.689). In the subgroup analysis of patients with stages IIIb
and IV lung cancer, the results were similar. Patients with
FIGURE 3. Survival curve of EGFR wild-type patients with
chest CT showing old TB lesions or not. Among patients
with tumor EGFR wild-type, those who had old TB lesions
(n  14) survived for a shorter period than those who did
not (n  70; 1-year survival rate 35.4% versus 82.1%, p 
0.009. EGFR, epidermal growth factor receptor; CT, com-
puted tomography; TB, tuberculosis.
FIGURE 4. Among patients with EGFR mutations, those
who had old TB lesions (n  58) survived for a shorter pe-
riod than those who did not (n  133; 1-year survival rate
84.6% versus 86.7%, p  0.035. EGFR, epidermal growth
factor receptor; TB, tuberculosis.
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lung cancer with TB infected or damaged lung may be more
vulnerable to second infection such as bacterial infection or
atypical pneumonia. Once those patients suffered from sec-
ond infection, repeated pneumonia and lethal nosocomial
pneumonia may occur due to poor pulmonary condition.
Patients are at risk for infection when receiving chemother-
apy, and scheduled chemotherapy may be delayed or omitted.
Disease progression is more likely to occur if the patients
could not receive treatment well. So the patient with an old
TB lesion had a poor prognosis. However, among patients
with tumor EGFR-activating mutation, they can continue
EGFR-TKI treatment even under active pulmonary infection,
and this treatment is effective for their cancer control. There-
fore, they have better lung cancer control.
A limitation of our study is that the patient selection
was confined to those who had adenocarcinoma of the lungs,
because most tumor EGFR mutations occur in adenocarci-
noma of the lungs. The relationship between TB and nonade-
nocarcinoma lung cancer is still unknown. In addition, this
was a retrospective study instead of a prospective case-
controlled study. Therefore, selection bias was inevitable, and
EGFR mutation rate in our study was higher than the ordinary
lung cancer population.
In conclusion, among patients with adenocarcinoma of
the lung, those who had scar cancer and old TB lesions had
a higher probability of having EGFR mutations, especially
exon 19 deletions. The patients with scar cancer had the
highest odds ratios for exon 19 deletions. These findings
suggest that there exists a relationship between pulmonary
TB and EGFR mutations in patients with adenocarcinoma of
the lungs.
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